查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439129

動物模型市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按動物類型、按應用、配銷通路區域和競爭細分

Animal Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Animal Type, By Application, By Distribution Channel Region and Competition
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球動物模型市場價值為 16.7 億美元，預計到 2028 年預測期內將出現強勁成長，複合CAGR為 7.64%。全球動物模型市場是生命科學行業中一個充滿活力且快速發展的領域，作為生物醫學研究和藥物開發的重要工具。動物模型包括從小鼠、大鼠到靈長類動物等多種物種，用於模擬人類生理和病理條件，使科學家能夠研究疾病、測試潛在的治療方法並獲得對生物機制的寶貴見解。由於製藥和生物技術研究投資的增加、個人化醫療需求的增加以及對創新療法和疫苗的需求，全球動物模型市場有望大幅成長。

市場概況
預測期 2024-2028
2022 年市場規模 16.7億美元
2028 年市場規模 25.8億美元
2023-2028 年CAGR 7.64%
成長最快的細分市場 老鼠
最大的市場 北美洲

動物模型市場的關鍵促進因素是慢性病和傳染病的日益流行，因此需要開發新型藥物和治療方法。動物模型在臨床前測試中發揮關鍵作用，幫助研究人員評估藥物的安全性和有效性，從而降低與人體試驗相關的風險。

該市場也受到基因工程進步的影響，允許創造出非常模仿人類狀況的基因改造動物。這些基因工程模型對於遺傳性疾病和個人化醫療方法的研究具有無價的價值。

此外，監管機構強調了倫理考量和動物福利的重要性，從而導致了體外測試和計算模型等替代方法的發展。然而，動物模型對於複雜的整體生物體研究仍然是不可或缺的，並且仍然是某些研究領域的黃金標準。

主要市場促進因素

慢性病盛行率上升

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球動物模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依動物類型（小鼠、大鼠、豚鼠、兔子、倉鼠、其他）
    • 按應用（癌症、免疫疾病、傳染病、其他）
    • 按配銷通路（製藥和生物技術公司、學術研究所、合約研究組織）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 依動物類型
    • 按應用
    • 按配銷通路
    • 按地區

第 5 章：亞太動物模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依動物類型
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲動物模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依動物類型
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美動物模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依動物類型
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲動物模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依動物類型
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東與非洲動物模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依動物類型
    • 按應用
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球動物模型市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Charles River Laboratories
  • The Jackson Laboratory
  • genOway
  • Taconic Biosciences, Inc.
  • Janvier Labs
  • Harbour BioMed
  • Crown Bioscience
  • Inotiv
  • BIOCYTOGEN
  • BioSpherix, Ltd.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 21633

Global Animal Model Market was valued at USD 1.67 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.64% through 2028. The global animal model market is a dynamic and rapidly evolving sector of the life sciences industry, serving as a crucial tool for biomedical research and drug development. Animal models, which include a wide range of species from mice and rats to primates, are utilized to mimic human physiological and pathological conditions, enabling scientists to study diseases, test potential treatments, and gain valuable insights into biological mechanisms. The global animal model market is poised for substantial growth due to increasing investments in pharmaceutical and biotechnology research, rising demand for personalized medicine, and the need for innovative therapies and vaccines.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.67 Billion
Market Size 2028USD 2.58 Billion
CAGR 2023-20287.64%
Fastest Growing SegmentMice
Largest MarketNorth America

One key driver of the animal model market is the growing prevalence of chronic diseases and infectious illnesses, necessitating the development of novel pharmaceuticals and treatments. Animal models play a pivotal role in preclinical testing, helping researchers assess drug safety and efficacy, thus reducing the risk associated with human trials.

The market is also influenced by advancements in genetic engineering, allowing for the creation of genetically modified animals that closely mimic human conditions. These genetically engineered models are invaluable for the study of genetic disorders and personalized medicine approaches.

Furthermore, regulatory agencies have emphasized the importance of ethical considerations and animal welfare, resulting in the development of alternative methods such as in vitro testing and computational modeling. However, animal models remain indispensable for complex, whole-organism studies and continue to be the gold standard in certain research areas.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a significant factor propelling the growth of the global animal model market. Chronic diseases, including cancer, diabetes, cardiovascular conditions, and neurological disorders, have reached epidemic proportions worldwide, imposing a substantial burden on healthcare systems and economies. In response to this health crisis, there is an ever-increasing demand for effective treatments and therapies. Animal models are at the forefront of preclinical research, providing a vital tool for understanding disease mechanisms and testing potential interventions.

Animal models serve as invaluable surrogates for human physiology, offering a means to simulate the complexities of chronic diseases and study their progression. Researchers can replicate the pathophysiological processes within animals, allowing for the investigation of disease etiology, drug efficacy, and safety profiles. This capability significantly reduces the inherent risks of advancing unproven therapies directly to human clinical trials.

Moreover, the use of animal models enables researchers to explore novel therapeutic avenues, develop innovative drug candidates, and fine-tune treatment regimens. By replicating the pathological conditions of chronic diseases in animal subjects, scientists can gain insights into potential therapeutic targets and mechanisms that would be challenging to investigate in any other way.

The animal model market's growth is further driven by the urgency to find solutions for these chronic diseases, as the prevalence of such conditions continues to climb. Pharmaceutical companies, biotechnology firms, and research institutions are increasingly reliant on animal models to facilitate their drug development processes. These models contribute to better understanding the safety, efficacy, and potential side effects of new pharmaceuticals, leading to accelerated research and development cycles.

Advancements in Genetic Engineering

Advancements in genetic engineering have emerged as a substantial driver behind the rapid growth of the global animal model market. These innovations have revolutionized the way researchers utilize animal models, making them more precise, versatile, and reflective of human physiological and pathological conditions. The ability to engineer animals with specific genetic modifications has opened new frontiers in biomedical research, drug development, and the study of genetic disorders.

Genetic engineering has allowed scientists to create genetically modified animals that closely mimic human genetic traits and diseases. By introducing, modifying, or silencing specific genes in animal models, researchers can create precise replicas of human conditions, including genetic disorders, cancers, and neurodegenerative diseases. These genetically engineered models provide a more accurate representation of the biological processes and pathways involved, enabling researchers to gain insights that were previously unattainable.

One of the key applications of genetically engineered animal models is in the development of personalized medicine. These models are essential in understanding how individual genetic variations influence drug responses and disease outcomes. Researchers can tailor treatments to specific genetic profiles, improving therapeutic effectiveness and reducing the risk of adverse reactions. This personalized medicine approach has the potential to transform healthcare by offering more targeted and efficient treatments.

Furthermore, genetic engineering has led to the creation of disease-specific animal models, which are instrumental in drug discovery and development. Pharmaceutical companies use these models to test potential drugs and therapies, allowing them to identify promising candidates and screen out ineffective or unsafe options. This accelerates the drug development process and reduces the time and cost associated with bringing new medications to the market.

Drug Discovery and Development

The process of drug discovery and development stands as a cornerstone of the global pharmaceutical and biotechnology industry, and it significantly drives the demand and growth of the global animal model market. Animal models have become indispensable tools in these industries, playing a pivotal role in every stage of the drug development pipeline. Their contribution to testing and validating potential drugs and therapies has streamlined research, improved the success rate of drug candidates, and reduced the time and costs associated with bringing new medications to market.

In the early stages of drug discovery, animal models are essential for evaluating the safety and efficacy of potential drug candidates. By administering experimental compounds to these models, researchers can assess how they interact with living organisms, determine their pharmacological properties, and identify any potential adverse effects. These critical insights are fundamental for making informed decisions about whether to advance a drug candidate to clinical trials.

Animal models also play a vital role in understanding the pharmacokinetics and pharmacodynamics of drugs, helping researchers determine the most appropriate dosages and administration routes for human trials. Additionally, these models are used to study the mechanisms of action and potential side effects of drug candidates, which is crucial for regulatory approval and patient safety.

Throughout clinical development, animal models are employed to test the effectiveness of drugs in treating specific diseases or conditions. These models provide critical data on treatment outcomes, helping researchers refine their approaches and optimize therapeutic regimens. They are particularly invaluable in studying complex diseases like cancer and neurological disorders, where in vivo models are essential to replicate the multifaceted nature of these conditions.

Key Market Challenges

Development of Ethical Concerns and Animal Welfare

The global animal model market, a linchpin of biomedical research and drug development, faces a formidable challenge from the escalating ethical concerns surrounding animal welfare. As society becomes increasingly conscious of the moral implications of using animals in research, these concerns have the potential to hinder the growth and evolution of the animal model market.

One of the central challenges is the ethical dilemma associated with animal experimentation. Many individuals, animal welfare organizations, and advocacy groups contend that the use of animals in research raises serious ethical questions regarding the treatment and suffering of sentient beings. The debate over the morality of using animals for scientific experiments has led to increasing calls for more stringent regulations and the development of alternative methods that do not involve animals.

As ethical concerns grow, there is greater scrutiny of animal welfare in research settings. Researchers are under increasing pressure to improve animal care, reduce suffering, and minimize the use of animals whenever possible. This, in turn, has raised the bar for standards and practices in the field, leading to more rigorous requirements for housing, enrichment, and veterinary care of research animals. These higher standards often translate into additional costs for research institutions and organizations.

Additionally, ethical concerns are accompanied by a push for transparency in animal research. The public and advocacy groups are calling for increased openness about the conditions and practices in laboratories, a demand that has implications for the animal model market.

Development of Alternative Testing Methods

The global animal model market, a cornerstone of biomedical research and drug development, is facing a challenge from the development of alternative testing methods. While these alternatives offer promise in terms of ethical considerations and sometimes cost efficiency, they have the potential to hinder the animal model market's growth and adaptation.

One of the primary challenges is the ongoing development and refinement of in vitro testing methods, computational modeling, and organ-on-a-chip technology. These alternatives aim to reduce or replace the use of animals in scientific research. While this shift toward alternative methods is driven by ethical concerns, it presents a hurdle for the animal model market, particularly in scenarios where animals have been the gold standard for comprehensive research.

In vitro testing, which involves conducting experiments in a controlled laboratory environment outside living organisms, is one of the main alternative approaches. It has the advantage of reducing animal suffering and can be less costly than maintaining animal colonies. However, these methods may not always fully replicate the complexity of whole-organism studies, which is a limitation when it comes to some types of research.

Key Market Trends

Advancements in Non-Rodent Models

Advancements in non-rodent models are emerging as a significant driver behind the growth of the global animal model market. While rodents, particularly mice and rats, have traditionally been the primary subjects of animal research, there is a growing trend towards diversification as researchers seek more physiologically relevant models that closely mimic human biology. Non-human primates, pigs, dogs, and other species are becoming increasingly valuable in various research applications, driving the market's expansion and adaptability.

Non-rodent animal models offer several advantages. They provide a closer approximation of human physiology, making them crucial for translational research where the goal is to bridge the gap between preclinical studies and human clinical trials. For example, non-human primates share a closer genetic and physiological resemblance to humans, making them invaluable in the development of therapies for diseases with complex genetic and immunological components.

In cancer research, canine models have proven highly relevant, as they naturally develop certain types of cancer that closely resemble human malignancies. These models allow researchers to study disease progression, test novel therapies, and refine treatment approaches. Similarly, non-human primates have been pivotal in advancing our understanding of infectious diseases, neuroscience, and vaccine development due to their physiological and immunological similarities to humans.

Advancements in non-rodent models are also contributing to the study of personalized medicine. Personalized medicine aims to tailor treatments to an individual's genetic and molecular profile, and non-rodent models are increasingly playing a role in developing and testing such tailored therapies.

Increased Use of Genetically Engineered Models

The increased use of genetically engineered models is serving as a powerful catalyst for the growth of the global animal model market. Genetic engineering techniques, particularly those involving CRISPR-Cas9 technology, have revolutionized the field of animal modeling, enabling researchers to create highly specific and tailored models that closely mimic human genetic conditions and diseases. This trend is reshaping the landscape of biomedical research and drug development.

Genetically engineered models offer several key advantages. They allow scientists to precisely manipulate the genes of animals to replicate specific human genetic traits, disorders, and mutations. This level of precision enables researchers to create animal models that closely mimic the genetic underpinnings of human diseases, making them invaluable tools for studying genetic disorders and the development of personalized medicine approaches.

The development of genetically engineered models has been instrumental in advancing research in areas like cancer, cardiovascular disease, neurodegenerative conditions, and rare genetic disorders. By introducing or modifying specific genes, researchers can create animal models that not only replicate the genetic aspects of these diseases but also allow for the testing of potential therapies and interventions.

Furthermore, genetically engineered models play a pivotal role in translational research, bridging the gap between basic science and clinical applications. They provide researchers with a more precise and tailored platform for studying the mechanisms of diseases, testing new drugs, and understanding the effects of genetic variations on disease outcomes.

This trend also aligns with the growing focus on personalized medicine, where treatments are tailored to an individual's genetic makeup and disease profile. Genetically engineered animal models are indispensable in understanding how specific genetic variations impact drug responses and disease outcomes. They contribute to the development of targeted therapies and the optimization of treatment regimens, making them a vital component of the evolving field of personalized medicine.

Segmental Insights

Animal Type Insights

Based on the Animal Type, Mice emerged as the dominant segment in the global market for Global Animal Model Market in 2022. Mice share a significant genetic and physiological resemblance to humans, making them a valuable model for studying various diseases and conditions. Their genomes have been well-studied and are highly informative for researchers, particularly in the field of genetics and genomics. Mice are relatively easy to genetically modify, which has been further facilitated by the development of advanced genetic engineering techniques like CRISPR-Cas9. Researchers can create mice models with specific genetic mutations or alterations to mimic human genetic conditions, making them a versatile tool for studying various diseases.

Application Insights

Based on the Application, Cancer emerged as the dominant segment in the global market for Global Animal Model Market in 2022. Cancer is a highly complex and multifaceted disease with a significant global health burden. The intricate nature of cancer, involving genetic mutations, tumor development, metastasis, and the complex interactions between cancer cells and the immune system, necessitates the use of sophisticated animal models for research. The global prevalence of cancer further underscores its importance as a research area, as it drives the demand for animal models that can accurately replicate various aspects of the disease. Translational research aims to bridge the gap between basic scientific findings and clinical applications. Animal models are pivotal in translational cancer research, helping scientists understand the transition from preclinical studies to human clinical trials. These models allow for the investigation of treatment responses and the development of therapeutics that can ultimately benefit patients.

Regional Insights

North America emerged as the dominant player in the global Animal Model Market in 2022, holding the largest market share. North America, particularly the United States, is home to a thriving and well-established biomedical and pharmaceutical industry. The presence of numerous pharmaceutical and biotechnology companies, academic research institutions, and medical centers drives the demand for animal models. These organizations heavily rely on animal models for preclinical research and drug development, contributing significantly to the market's growth. North America boasts a robust research infrastructure, featuring state-of-the-art research facilities, well-equipped laboratories, and advanced technologies. This strong infrastructure supports the breeding, maintenance, and experimentation with animal models, making it an attractive region for research that depends on these models.

Key Market Players

Charles River Laboratories

The Jackson Laboratory

genOway

Taconic Biosciences, Inc.

Janvier Labs

Harbour BioMed

Crown Bioscience

Inotiv

BIOCYTOGEN

BioSpherix, Ltd

Report Scope:

In this report, the Global Animal Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Animal Model Market, By Animal Type:

  • Mice
  • Rat
  • Guinea Pigs
  • Rabbits
  • Hamsters
  • Others

Global Animal Model Market, By Application:

  • Cancer
  • Immunological Disease
  • Infectious Disease
  • Others

Global Animal Model Market, By Distribution Channel:

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institute
  • Contract Research Organization

Global Animal Model Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Animal Model Market.

Available Customizations:

  • Global Animal Model Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Animal Model Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Animal Type (Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Others)
    • 4.2.2. By Application (Cancer, Immunological Disease, Infectious Disease, Others)
    • 4.2.3. By Distribution Channel (Pharmaceutical & Biotechnology Companies, Academic Research Institute, Contract Research Organization)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Animal Type
    • 4.3.2. By Application
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Animal Model Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type
    • 5.2.2. By Application
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Animal Model Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Animal Type
        • 5.3.1.2.2. By Application
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Animal Model Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Animal Type
        • 5.3.2.2.2. By Application
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Animal Model Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Animal Type
        • 5.3.3.2.2. By Application
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Animal Model Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Animal Type
        • 5.3.4.2.2. By Application
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Animal Model Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Animal Type
        • 5.3.5.2.2. By Application
        • 5.3.5.2.3. By Distribution Channel

6. Europe Animal Model Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Animal Model Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Animal Model Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Animal Model Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Animal Model Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Animal Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Animal Model Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Animal Type
        • 6.3.5.2.2. By Application
        • 6.3.5.2.3. By Distribution Channel

7. North America Animal Model Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Animal Model Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Animal Model Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Animal Model Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel

8. South America Animal Model Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Animal Model Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Animal Model Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Animal Model Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Animal Model Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Animal Model Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Animal Model Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Animal Model Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Animal Model Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Charles River Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. The Jackson Laboratory
  • 14.3. genOway
  • 14.4. Taconic Biosciences, Inc.
  • 14.5. Janvier Labs
  • 14.6. Harbour BioMed
  • 14.7. Crown Bioscience
  • 14.8. Inotiv
  • 14.9. BIOCYTOGEN
  • 14.10. BioSpherix, Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer